|
SOFOSBUVIR: CURRENT INFORMATION FOR CHRONIC HEPATITIS C TREATMENT |
|---|---|
| รหัสดีโอไอ | |
| Creator | Karunrat Tewthanom |
| Title | SOFOSBUVIR: CURRENT INFORMATION FOR CHRONIC HEPATITIS C TREATMENT |
| Publisher | Faculty of Pharmacy, Silpakorn University |
| Publication Year | 2560 |
| Journal Title | Thai Bulletin of Pharmaceutical Science (TBPS) |
| Journal Vol. | 12 |
| Journal No. | 1 (January-June)2017 |
| Page no. | 91-107 |
| Keyword | Sofosbuvir, hepaptitis C virus, treatment, chronic hepatitis C infection |
| ISSN | 1686-9540 |
| Abstract | Sofosbuvir, an anti-hepatitis C virus medication that approved from FDA in treatment chronic hepatitis C infection by combination with standard medication therapy; interferon and ribavirin, and combination with new non-interferon based anti-viral regimens. According to drugs' properties, it is nucleotide analog that inhibits HCV NS5B polymerase then terminate the virus replication and no viral assembly. The drug is rapid absorbed and turn to be a metabolite; GS-331007. The drug's half-life is 0.4 h, while the metabolite has half-life 27 h. The elimination is metabolism to active metabolite and excretion via kidney (the metabolite is excreted by kidney 78%). The dose adjustment is unnecessary in mild to moderate kidney and liver diseases but none of study in severe kidney and liver diseases population. Several studies confirmed efficacy in treatment of chronic hepatitis C virus infection, both concomitant with standard regimens or combination with non-interferon based regimens. The most common adverse effect is fatigue and usually come from combination drugs that use in standard regimens. Focus on adverse effects, the most adverse drug reaction is fatigue and usually comes from the combination drugs in treatment regimens. The resistance rate found low because the drug target is the invariable part of virus component. Consider for interaction issue, according to affinity in binding to P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), drugs that can activate P-gp in gastrointestinal tracts (example; Rifampicin or St. John's wort) may decrease Sofosbuvir concentration in blood. Leading, treatment failure due to small amount of drug is in the body. Therefore, it is not recommended to administration Sofosbuvir with drugs that can activate P-gp. From the drug properties and information of previous clinical studies found that Sofosbuvir is an interesting drug to use as an alternative in treatment chronic hepatitis C infection. It can be able to use in combination with standard regimens (interferon and ribavirin) or use with non-interferon based regimens in case of interferon intolerance. These strategies give more alternative therapeutic options to the patients. |
